Spero Therapeutics (NASDAQ:SPRO) has been assigned a consensus rating of “Hold” from the seven research firms that are presently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company. The average 12-month price target among analysts that have covered the stock in the last year is $27.67.
SPRO has been the subject of several analyst reports. Zacks Investment Research upgraded shares of Spero Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 target price for the company in a research note on Tuesday, January 30th. Oppenheimer set a $30.00 target price on shares of Spero Therapeutics and gave the company a “buy” rating in a research note on Thursday, January 11th. Cantor Fitzgerald set a $27.00 target price on shares of Spero Therapeutics and gave the company a “buy” rating in a research note on Thursday, April 12th. Finally, ValuEngine upgraded shares of Spero Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd.
Shares of SPRO stock traded down $0.25 during trading hours on Wednesday, hitting $12.91. The company’s stock had a trading volume of 30,735 shares, compared to its average volume of 39,614. The company has a market capitalization of $189.10 and a P/E ratio of -0.72. Spero Therapeutics has a 12-month low of $9.66 and a 12-month high of $19.00.
Institutional investors and hedge funds have recently bought and sold shares of the stock. California Public Employees Retirement System acquired a new position in shares of Spero Therapeutics in the 4th quarter valued at $294,000. Atlas Venture Associates IX LLC acquired a new position in Spero Therapeutics during the fourth quarter worth $16,179,000. BVF Inc. IL acquired a new position in Spero Therapeutics during the fourth quarter worth $12,093,000. Rock Springs Capital Management LP acquired a new position in Spero Therapeutics during the fourth quarter worth $6,169,000. Finally, AWM Investment Company Inc. acquired a new position in Spero Therapeutics during the fourth quarter worth $4,112,000. Hedge funds and other institutional investors own 46.28% of the company’s stock.
About Spero Therapeutics
Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; and SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting.
Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.